A Democratic lawmaker is raising new concerns about a Food and Drug Administration program designed to drastically shorten the review of certain drugs. The initiative by FDA Commissioner Marty Makary promises ultra-fast reviews for drugs that align with “national priorities.” But the effort has become a flashpoint for controversy outside and inside the agency. Rep. Jake Auchincloss of Massachusetts sent a letter Tuesday questioning the legal underpinning of the program and asserting that the agency isn't following federal disclosure requirements. Specifically, Auchincloss says the agency has failed to file financial disclosure forms for eight senior FDA officials involved in the program.
